Maine Medicine Weekly Update - 12/17/2020  (Plain Text Version)

Return to Graphical Version

 

In this issue:
•  Advisory Panel Recommends Moderna Vaccine, FDA Expected to Authorize Emergency Use
•  Update to Our Special Edition Wednesday Vaccine Newsletter
•  FDA Authorizes First OTC COVID-19 Test
•  Maine Public Radio Reports 32 COVID-19 Cases Linked To Bangor Hospital Outbreak
•  MaineCare Section 17 Assertive Community Treatment (ACT) Service Cap
•  Attention FQHCs and RHCs: Reimbursing Telehealth Services, CR 98696
•  Current FDA Drug Shortages
•  Not Much COVID Relief Movement from Congress
•  Maine CDC Physicians To Host Regular Clinician COVID Vaccine Info Sessions
•  PPE Available Through the MMA & ActionPPE
•  Maine Medical Association Enduring Education Opportunity
•  MICIS Opioid Prescribing Presentation & Individual Academic Detailing Sessions
•  Hanley's PELI Advanced Course Enrollment is OPEN!
•  A Message from Maine Responds: Volunteer Opportunity
MAINE LEGISLATURE
•  State Legislative Committees Announced
UPCOMING EVENTS
•  Upcoming Specialty Society Programs & Meetings
•  Webinar: “Radon Risk Reduction: The Current Policy Landscape in the US and the Maine Perspective” January 12, 2020
•  Caring for LGBTQ+ Youth in Maine - Emphasis on the 'T' - Half-day Symposium on Saturday, January 23
•  MOA VIRTUAL Midwinter Symposium - Feb 12-14, 2021
•  Maine CDC Annual Prevention Professionals Conference - March 2-3, 2021
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Behavioral Health Clinician
•  Psychiatric Nurse Practitioner
•  Physician (BC/BE in Family Medicine)

 

Advisory Panel Recommends Moderna Vaccine, FDA Expected to Authorize Emergency Use

The US FDA’s Vaccines and Related Biological Products Advisory Committee voted Thursday to recommend emergency use authorization (EUA) of Moderna’s coronavirus vaccine. The FDA will now review the advisory committee's vote and decide whether to authorize emergency use nationwide.

 

The US FDA’s Vaccines and Related Biological Products Advisory Committee voted Thursday to recommend emergency use authorization (EUA) of Moderna’s coronavirus vaccine. The FDA will now review the advisory committee's vote and decide whether to authorize emergency use nationwide.

FDA Moderna Briefing Document (PDF)

FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting

The excitement and expectations associated with the Moderna vaccine cannot be overstated and it will surely benefit non-hospital based outpatient physicians and staff. It is more easily transported and stored, making it more accessible to broader groups, including independent physician practices located in both suburban and rural areas. Unlike Pfizer, it can be stored at normal freezer temperatures and it comes in much smaller batches.

Last week, Maine CDC released initial projections that 24,200 doses are expected for first week of a Moderna delivery. Of the 24,200 total, 22,700 will go to hospitals and another 1,500 to be split between Androscoggin Home Health Services, Mid Coast Parkview Health (CHANS), MaineHealth Care at Home, Houlton Band of Maliseets, and Maine EMS.

Related FDA information:

COVID-19 Vaccines (FDA)

COVID-19 ACIP Vaccine Recommendations (ACIP)

Emergency Use Authorization for Vaccines Explained

Emergency Use Authorization for Vaccines to Prevent COVID-19

Development and Licensure of Vaccines to Prevent COVID-19

Washington Post: FDA vows to move 'rapidly’ to authorize second coronavirus vaccine